Juan Carlos Restrepo

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

IMPACT OF THE RECURRENCE OF HEPATITIS C VIRUS INFECTION AFTER LIVER TRANSPLANTATION ON THE LONG-TERM VIABILITY OF THE GRAFT1

Alberto Sánchez‐Fueyo, Juan Carlos Restrepo, Llorenç Quintó et al. · Transplantation · 2002 · 162 citations

Medicine, Infectious Diseases, Hepatology +16

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study

Juan Pablo Arab, Luis Antonio Díaz, Natalia Baeza et al. · Journal of Hepatology · 2021 · 141 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares‐da‐Silva et al. · Annals of Hepatology · 2020 · 139 citations · Full text

Medicine, Endocrinology, Internal Medicine +14

Fossil or bioenergy? Global fuel market trends

Diana A. Londoño-Pulgarín, Giovanny Cardona-Montoya, Juan Carlos Restrepo et al. · Renewable and Sustainable Energy Reviews · 2021 · 137 citations

Public Affairs, Economics, Natural Resource Economics +12